Key Highlights
- Cell Q™ automates quality control, drastically increasing throughput with capacity for up to 6,000 batches/year.
- Designed to complement Cell Shuttle™, it offers an end-to-end solution for enhanced cell therapy production.
- Exclusive to Cellares’ Smart Factories, soon expanding to the EU and Japan.
Source: Business Wire
Notable Quote
- “Cell Q™ was designed to match the throughput of our Cell Shuttle™ platform. This enables the Cellares IDMO to offer a real end-to-end solution for our customers, providing 10 times higher capacity and up to 50% lower batch price,” – Fabian Gerlinghaus, CEO at Cellares
SoHC's Take
Cellares is spearheading a revolution in cell therapy manufacturing with its latest innovation, Cell Q™. This automated QC workcell is set to transform the industry by tackling the traditionally manual and costly quality control processes. By integrating Cell Q™ with their Cell Shuttle™ platform, Cellares is not only optimizing production but also ensuring significant cost reductions and improved reproducibility at their IDMO Smart Factories. As they expand into European and Japanese markets, their role as a pivotal leader in the cell therapy manufacturing sector will likely grow, marking an exciting phase for global healthcare innovations.
